Natalia shares her point of view indicating how improvements in technology are transforming the role of CDMOs, especially as they adopt platform-based approaches, significantly reducing development timelines while ensuring scalability and productivity up to the commercial phase. She adds how continuous automation and monitoring further accelerate development and improve predictive capabilities through enhanced data collection.
At VIVEbiotech, a GMP CDMO, this approach is applied through a versatile, scalable, and cost-effective plug-and-play manufacturing platform for lentiviral vectors that shortens setup phases and supports all stages up to commercialization. However, alongside automation and platform-based strategies, maintaining deep specialization and expertise in virology and bioprocessing is crucial for CDMOs to remain strategic contributors in innovative fields like cell and gene therapy.
Read the full opinion of Natalia and several other experts in the field in the whole article here: https://www.pharmasalmanac.com/articles/how-are-advancements-in-technology-reshaping-the-roles-and-capabilities-of-cdmos-and-cros-in-the-drug-development-life-cycle